Beijing Zhipeptide Biotechnology

Zhipeptide is a Beijing-based biotechnology company specializing in the discovery and development of next-generation peptide therapeutics for metabolic diseases. Leveraging an AI-driven computational design platform, the company focuses on multi-target agonists such as GLP-1, GIP, and glucagon receptor ligands to treat obesity and type 2 diabetes. Their lead candidate, ZP-001, is a long-acting triple agonist designed for superior weight loss and glycemic control. Zhipeptide aims to optimize peptide stability and efficacy through innovative structural modifications. The company has secured significant venture capital funding to advance its pipeline into clinical stages.